Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia.

ABSTRACT:

Aims

Paliperidone palmitate 3-month (PP3M) represents a new long-acting injectable antipsychotic therapeutic option. This review aims: 1) to summarize available data relating to efficacy, safety, tolerability and costs of PP3M; 2) to describe hospitalization rate, occupational status, treatment preference, satisfaction, adherence and caregiver burden of patients with schizophrenia who participate in PP3M clinical trials; 3) to examine ethical implications, pros and cons of PP3M use and 4) to propose study designs to further assess PP3M.

Methods

On August 21, 2017, a search on PubMed about PPM3, without any filter restriction, was conducted and all available records were analyzed. Records written in a language other than English were excluded.

Results

Twenty-two record

SUBMITTER: Brasso C 

PROVIDER: S-EPMC5683787 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature